MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

27 8

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.93

Максимум

27.53

Ключови измерители

By Trading Economics

Приходи

7M

-102M

Продажби

996K

8.5M

Марж на печалбата

-1,208.257

Служители

509

EBITDA

17M

-97M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+56.93% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

696M

2.6B

Предишно отваряне

19

Предишно затваряне

27

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.10.2025 г., 20:45 ч. UTC

Печалби

Costco Wholesale Sales Climb in September, Early October

8.10.2025 г., 20:12 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

TaskUs Shares Fall After Holders Reject Take-Private Deal

8.10.2025 г., 16:39 ч. UTC

Значими двигатели на пазара

Mining Shares Rise as Gold Prices Soar

8.10.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

8.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Profit-Taking -- Market Talk

8.10.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Finance Acquisition Using Internal Funds

8.10.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8.10.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8.10.2025 г., 21:54 ч. UTC

Пазарно говорене
Печалби

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8.10.2025 г., 21:30 ч. UTC

Пазарно говорене

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8.10.2025 г., 21:26 ч. UTC

Пазарно говорене
Печалби

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 19:15 ч. UTC

Пазарно говорене

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8.10.2025 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8.10.2025 г., 18:47 ч. UTC

Пазарно говорене

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Will Remain a Publicly Traded Co >TASK

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8.10.2025 г., 18:07 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Edging Up in September -- Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.10.2025 г., 15:57 ч. UTC

Пазарно говорене

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8.10.2025 г., 15:56 ч. UTC

Пазарно говорене

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8.10.2025 г., 15:53 ч. UTC

Пазарно говорене

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8.10.2025 г., 15:43 ч. UTC

Придобивния, сливания и поглъщания

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8.10.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

56.93% нагоре

12-месечна прогноза

Среден 40.63 USD  56.93%

Висок 80 USD

Нисък 20 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

9

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat